AMD patients undermonitored, undertreated in real-world scenarios, observational study shows

COPENHAGEN, Denmark — An observational study conducted at several locations in Europe, Australia, Canada and Venezuela showed that, in a real-world scenario, treatment with ranibizumab for wet age-related macular degeneration had poorer-than-expected visual outcomes due to irregular monitoring and a low number of treatments per year. "In clinical practice, as-needed or treat-and-extend dosing regimens are generally adopted, but on the whole they don’t seem to produce good results," Sobha Sivaprasad, MD, at the meeting of the European Society of Ophthalmology.